AppliedMicro Announces the Availability of X-C1(TM) Development Kits
Nov 18 14
Applied Micro Circuits Corporation announced the immediate availability of its X-C1(TM) Development Kits, low-cost, low-power development systems featuring the company's innovative X-Gene(TM) Server-on-a-Chip (SoC) solution. The systems come in two versions -- Plus and Basic -- and each provides a native ARM 64-bit environment for developers working on both mobile and server applications. Key Features: X-C1 Development Kit Plus: X-Gene 8-core ARM 64-bit CPU at 2.4 GHz; Interfaces on the board include 1GbE, 10GbE, SATA Gen3, PCIe Gen3, USB, SDIO and industry standard debug interfaces; Kit includes a Mini-ITX desktop chassis with power supply and 500GB SATA drive; Operating system offerings include AppliedMicro Linux, Ubuntu, Fedora and OpenSuse; Pricing: Standard MSRP is $2,495. With AppliedMicro's current developer promotion, qualified buyers can purchase the board for $1,395. X-C1 Development Kit Basic: X-Gene 8-core ARM 64-bit CPU at 1.6 GHz; Interfaces on the board include 1GbE, SATA Gen3, PCIe Gen3, USB, SDIO and industry standard debug interfaces; Kit includes Mini-ITX power supply and serial-USB FDTI console cable; Operating system offerings include AppliedMicro Linux, Ubuntu, Fedora and OpenSuse; Pricing: Standard MSRP is $1,495. With AppliedMicro's current developer promotion, qualified buyers can purchase the board for $895.
Applied Micro Circuits Corporation Collaborates with Red Hat and Cirrascale to Deliver an Evaluation Platform for HPC Clusters to Lawrence Livermore National Laboratory
Nov 17 14
Applied Micro(R) Circuits Corporation, announced collaboration with Red Hat(R) and Cirrascale(R) to deliver a high performance computing (HPC) cluster based on the world's first ARM(R) 64-bit X-Gene(TM) Server on a Chip(TM) to Lawrence Livermore National Laboratory(R). This cluster will be tested and evaluated as a platform for HPC and Big Data technologies. The X-Gene cluster as developed by Cirrascale consists of 78 RM1905D 1U dual-node rackmount servers provisioned for high performance computing in a custom chassis supporting one to four GPUs in a system. X-Gene is the first processor of its kind, featuring 8 custom, enterprise-class, high-performance ARMv8-A cores running at 2.4Ghz, with 4 memory channels capable of accommodating up to 512GBytes of high speed DDR3 memory, Multiple integrated 10Gigabit Ethernets, 17 lanes of PCIe Gen 3.0; the device is the first and most advanced ARM 64-bit architecture with unique network and storage off-load engines. The highly integrated, purpose-built X-Gene platform delivers the high performance, low total cost of ownership (TCO) for private cloud, public cloud, High Performance Computing and enterprise applications. The Cirrascale RM1905D HPC Development Platform is an ideal solution to deploy ARM 64-bit architecture in production ready environments. The RM1905D Development Platform delivers twice the density by providing two individual nodes per 1U, effectively doubling the density over standard 1U rackmount implementations.
Applied Micro Circuits Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014; Reports Impairment Charges; Provides Earnings Guidance for the Third Quarter Ending December 2014
Oct 28 14
Applied Micro Circuits Corporation reported unaudited consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, net revenues were $40,945,000 against $55,387,000 a year ago. Operating loss was $9,333,000 against $32,767,000 a year ago. Loss before income taxes was $11,445,000 against $32,191,000 a year ago. Net loss was $11,717,000 or $0.15 per basic and diluted share against $32,383,000 or $0.45 per basic and diluted share a year ago. Non-GAAP net loss was $5,044,000 or $0.06 per diluted share against non-GAAP net income of $2,010,000 or $0.03 per diluted share a year ago. Net cash used for operating activities was $7,490,000 against $17,547,000 a year ago. Purchase of property and equipment was $2,756,000 against $1,744,000 a year ago.
For the six months, net revenues were $91,217,000 against $109,535,000 a year ago. Operating loss was $22,854,000 against $25,517,000 a year ago. Loss before income taxes was $24,651,000 against $21,146,000 a year ago. Net loss was $24,782,000 or $0.32 per basic and diluted share against $21,526,000 or $0.30 per basic and diluted share a year ago. Non-GAAP net loss was $4,889,000 or $0.06 per diluted share against non-GAAP net income of $3,445,000 or $0.05 per diluted share a year ago. Net cash used for operating activities was $14,027,000 against $35,359,000 a year ago. Purchase of property and equipment was $7,300,000 against $2,023,000 a year ago.
For the December quarter 2014, the company expects gross margins in the range of 55% to 59%. Non-GAAP operating expenses are expected to be in the range of $28 million to $29 million. The company expects earnings per share to be a loss of $0.10, plus or minus $0.02 on a non-GAAP basis. Importantly, the company expects the cash flow from base business will continue to support investment in X-Gene. The company expects product and licensing revenues to be of $36 million, plus or minus $2 million.
The company reported impairment of a strategic investment was $2,500,000 for the second quarter ended September 30, 2014.